Two Novel and Two Recurrent Variants of the ADAR1 Gene in Three Chinese Families with Dyschromatosis Symmetrica Hereditaria
Yunxia Zhu,Deng Zhang,Liang Wu,Xiaoliang Ouyang,Shengcai Zhu,Xiuping Wang,Zhen Xiao,Yanping Tan,Chunming Li
DOI: https://doi.org/10.2147/ccid.s477138
2024-10-25
Clinical Cosmetic and Investigational Dermatology
Abstract:Yunxia Zhu, 1 Deng Zhang, 1 Liang Wu, 1 Xiaoliang Ouyang, 2 Shengcai Zhu, 1 Xiuping Wang, 1 Zhen Xiao, 3 Yanping Tan, 4 Chunming Li 1 1 Department of Dermatology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China; 2 Department of Plastic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China; 3 Department of Dermatology, Taiyuan Central Hospital, Taiyuan, Shanxi, People's Republic of China; 4 Department of Dermatology, Jiangxi Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi, People's Republic of China Correspondence: Chunming Li, Department of Dermatology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China, Tel/Fax +86 79186278821, Email Purpose: Dyschromatosis symmetrica hereditaria (DSH) is a rare autosomal dominant inherited pigmentary dermatosis. The gene responsible for DSH has been identified as adenosine deaminase acting on RNA1 ( ADAR1 ). This study aimed to identify the causative variants in the ADAR1 gene in three Chinese families with DSH. Patients and Methods: Data and blood samples were collected from three Chinese families with DSH. Whole-exome and Sanger sequencing were performed to detect pathogenic gene mutation in the patients. Bioinformatics tools were used to predict the pathogenicity of the variants. Results: Four heterozygous ADAR1 variants were identified, including two novel missense variants c.2369G>C (Arg790Pro), and 503C>T (Pro168Leu), and two previously reported variants: c.3232C>T(R1078C), and c.1472C>G (p.S491X). The novel c.503C>T variant was predicted as "deleterious" (score =− 2.704) by PROVEAN, and "probably damaging" (score = 1) by PolyPhen2. The other novel variant c.2369G>C was also predicted as "deleterious" (score =− 4.167) by PROVEAN, "probably damaging" (score = 1) by PolyPhen2, and "disease-causing" (p = 0.999) by Mutation Taster. Conclusion: Two novel ADAR1 variants were found in Chinese patients with DSH. This research has expanded the ADAR1 gene database for DSH, enhancing our comprehension of the underlying mechanisms. Keywords: dyschromatosis symmetrica hereditaria, adenosine deaminase acting on RNA1, mutation analysis, Chinese Dyschromatosis symmetrica hereditaria (DSH, OMIM#127400), also called symmetric dyschromatosis of the extremities or reticulate acropigmentation of Dohi, is a rare autosomal dominant inherited pigmentary dermatosis. 1 It is characterized by intermingled hyper- and hypopigmented spots primarily located on the dorsal aspects of the extremities. Some affected individuals may also exhibit freckle-like lesions on the face. 2 This condition typically manifests in infancy or childhood, worsens during adolescence, and persists throughout life. 3 DSH is caused by pathogenic mutations in the adenosine deaminase acting on RNA1 ( ADAR1 ) gene, which encodes RNA-specific adenosine deaminase 1 composed of 1,226 amino acid residues. 4 The ADAR1 protein acts as an RNA editing enzyme by catalyzing the deamination of adenosine (A) to inosine (I) in double-stranded RNA (dsRNA) substrate during transcription. 5 ADAR1 activity is involved in various processes, including viral inactivation, structural modification of proteins, and cell survival. 6 To investigate the pathogenic variant of the ADAR1 gene, we conducted whole-exome sequencing (WES) and Sanger sequencing on three Chinese families with DSH. Furthermore, we utilized bioinformatics tools to predict the pathogenicity of the variants. Three Chinese families with DSH were enrolled in this study. We collected detailed clinical data and pictures. Approximately 5 mL of peripheral blood or 1 mL of saliva was collected from the participants. All procedures were approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University. Informed consent was obtained from all individual participants included in the study. Genomic DNA was extracted from peripheral blood samples using a Puregene Blood Core Kit B (QIAGEN, Hilden, Germany) following standard procedures. WES was conducted using the SureSelectXT Human All Exon V6 kit (Agilent Technologies, Santa Clara, USA). For each subject, 1.5 μg of genomic DNA was utilized to prepare a captured library, which was subsequently sequenced on a HiSeq X Ten platform (Illumina, San Diego, USA), generating 150 bp paired-end reads. The average depth of target r -Abstract Truncated-
dermatology